<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69118">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206022</url>
  </required_header>
  <id_info>
    <org_study_id>13 6932 03</org_study_id>
    <nct_id>NCT02206022</nct_id>
  </id_info>
  <brief_title>Remifentanil And Local Anesthesia Compared With Local Anesthesia For The Insertion Of Central Venous Catheters</brief_title>
  <acronym>REMIDOLCATH</acronym>
  <official_title>REMIFENTANIL AND LOCAL ANESTHESIA COMPARED WITH LOCAL ANESTHESIA FOR THE INSERTION OF CENTRAL VENOUS CATHETERS IN AWAKE PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there is no reference protocol for Central Venous Catheter (CVC) insertion
      assuring analgesia, anxiolysis and safety. Medical teams use various levels of analgesia and
      anesthesia to realize this gesture, from single local anesthesia to general anesthesia.
      Remifentanil has been shown to decrease pain scores for insertion and removal of long-term
      central venous access. Remifentanil is also often employed for pediatric or labor analgesia
      for short acts as procedural sedation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal pain score on numeric rating scale (NRS) will be assessed after the insertion</measure>
    <time_frame>up to 60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient's anxiety by the Face Anxiety Scale</measure>
    <time_frame>up to 60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and physician's satisfaction by a 10-points numeric rating scale</measure>
    <time_frame>up to 60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of realized punctions</measure>
    <time_frame>up to 60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Local Anesthesia</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Pain's evaluation for Remifentanil Group</description>
    <arm_group_label>Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>CVC pain's evaluation after local anesthesia + placebo infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than 18 years old

          -  eligible for CVC insertion

        Exclusion Criteria:

          -  pregnancy

          -  patients who can't give their consent

          -  contra-indications to remifentanil infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean RUIZ, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean RUIZ, MD, PhD</last_name>
    <phone>05 61 77 97 92</phone>
    <phone_ext>+33</phone_ext>
    <email>ruiz.jean@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean RUIZ, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>BÃ©atrice RIU, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent MINVILLE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie BRUNEL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel OLIVIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 21, 2017</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Venous Catheter</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>local anesthesia</keyword>
  <keyword>pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
